HER2-positive breast cancer: Incidence, prognosis, and treatment options. Am J Cancer 2003; 2 (3): 169-79.Estevez LG, Seidman AD. HER2-positive breast cancer: incidence, prognosis, and treatment options. Am J Cancer. 2003; 2 :169–179....
[7] Agostinetto E, Rediti M, Fimereli D, et al. HER2-low breast cancer: molecular characteristics and prognosis. Cancers (Basel) 2021;13(11):2824. [8] Spring LM, Barlow WE, Bardia A, et al. Impact of HER2 low status on clinical outcomes in participants with 1-3 positive lymph no...
Trastuzumab resistance is one of the causes of poor prognosis in patients with human epidermal growth factor receptor 2 (HER2)-positive (HER2+) breast cancer (BC). The truncated isoform of dopamine- and cAMP-regulated phosphoprotein (t-DARPP) has been reported to be involved in trastuzumab thera...
[8] Maurer C, Tulpin L, Moreau M, et al. Risk factors for the development of brain metastases in patients with HER2-positive breast cancer. ESMO Open. 2018 Oct 24;3(6):e000440. [9] Darlix A, Louvel G, Fraisse J, et al. Impact of breast cancer molecular subtypes on the inciden...
Matthew,James,Ellis - 《J Natl Cancer Inst》 被引量: 3发表: 2014年 Early Stage HER2 Positive Breast Cancers Not Achieving A pCR From Neoadjuvant Trastuzumab Or Pertuzumab Based Regimens Have An Immunosuppressive Phenotype Early stage HER2-positive breast cancers not achieving a pCR From neoadjuvant...
16. Loibl S, Untch M, Buyse M, et al. Pathologic complete response (pCR) and prognosis following neoadjuvant chemotherapy plus anti-HER2 therapy of HER2-positive early breast cancer (EBC). Cancer Res. 2020;80(4_Suppl):P5-06-02.
Human epidermal growth factor receptor 2 (HER2) positive breast cancer accounts for 20–25% of all breast cancers. Multiple HER2-targeted therapies have been developed over the last few years, including the tyrosine kinase inhibitors (TKI) lapatinib, neratinib, tucatinib, and pyrotinib. These drug...
2023年11月17日,在结束T-DM1治疗后,采用剂量递增方案序贯奈拉替尼强化辅助治疗。具体用药剂量为:第1周,120g(3片)/d;第2周,160mg(4片)/d;第3-52周,240mg(6片)/d。 在用药第一个月期间,患者出现Ⅱ级腹泻(4-5次/月),按...
Breast cancer remains an important public health concern, claiming more than a hundred lives every day in the US alone, and its often arduous treatment takes a significant toll on patients25. Breast cancer is divided into several subtypes, including HER2-positive tumors, which are defined by an...
[15]Llombart-Cussac A,et al.HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer(PAMELA):an open-label,single-group,multicentre,phase 2 trial.Lancet Oncol 2017;18:545–54. ...